Chargement en cours...
Nivolumab in relapsed/refractory Hodgkin lymphoma: towards a new treatment strategy?
Chemo-refractory Hodgkin lymphoma (HL), especially after failure of high-dose therapy and autologous stem cell transplantation (ASCT), has a very poor prognosis. Nivolumab, an anti-PD-1 monoclonal antibody, demonstrated durable responses and manageable toxicity in a significant proportion of HL pati...
Enregistré dans:
| Publié dans: | Am J Blood Res |
|---|---|
| Auteurs principaux: | , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
e-Century Publishing Corporation
2021
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8303013/ https://ncbi.nlm.nih.gov/pubmed/34322289 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|